Harvard Apparatus Regenerative Technology Inc. HRGN

Full chart Compare

Set alert

2.09 USD 0.00 (+0.00%)

At closeNov 10, 2026, 4:00 PM EST

2.09 Day range 2.10

0.96 52-week range 2.46

YTD: +13.59%
1 year: +4.50%

News

6 months ago globenewswire.com Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic Holliston, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
9 months ago globenewswire.com Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease HOLLISTON, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
11 months ago defenseworld.net Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG) Arch Therapeutics (OTCMKTS:ARTH - Get Free Report) and Biostage (OTCMKTS:BSTG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two…
2 years ago globenewswire.com Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights Holliston, MA, May 13, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
3 years ago globenewswire.com Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc . (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the…
3 years ago prnewswire.com Activated University of Michigan as The Second Site for Clinical Trial in Severe Esophageal Disease HOLLISTON, Mass. , Aug. 28, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage…
3 years ago prnewswire.com Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency HOLLISTON, Mass. , Aug. 21, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage…
3 years ago prnewswire.com Harvard Apparatus Regenerative Technology Reports Second Quarter 2023 Financial Results HOLLISTON, Mass. , Aug. 14, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage…
3 years ago prnewswire.com Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results HOLLISTON, Mass. , Aug. 9, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("HRGN" or the "Company"), a clinical-stage biotechnology company developing the…
3 years ago prnewswire.com Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease HOLLISTON, Mass. , July 18, 2023 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing the technology to regenerate organs…
3 years ago prnewswire.com Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, Mass.
3 years ago seekingalpha.com Biostage, Inc. (BSTG) Q3 2022 Earnings Call Transcript Biostage, Inc. (OTC:BSTG) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM ET Company Participants David Green - Interim Chief Executive Officer Joe Damasio - Chief Financial Officer…